Overview

Effect of Lactoferrin in Pneumonia Treatment

Status:
Not yet recruiting

Trial end date:
2024-08-01

Target enrollment:
0

Participant gender:
All

Summary

Pneumonia is defind as the inflammation of lung tissue caused by an infectious agent that results in acute respiratory signs and symptoms. Community acquired pneumonia (CAP) is a major cause of morbidity and increased health care costs. In developing nations, pneumonia remains a significant cause of mortality in children. Pneumonia occurs in 30 to 45 of every 1,000 children under 5 years of age; it is less common in 5- to 9-year olds (16 to 22/1,000) and in older children (7 to 16/1,000). Streptococcus pneumoniae is the primary bacterial cause of pneumonia in infants and children. Viral etiologies become less prevalent and mycoplasmal and chlamydial infections become more prevalent with increasing age

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assiut University

Treatments:

Lactoferrin

Criteria

Inclusion Criteria:

- Pneumonia patients

- from the age of one month to the age of 18 years .

Exclusion Criteria:

Neonates and any children with :

- immune deficiency

- congenital heart disease

- neuromascular disorder

- genetic syndromes